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ESMO Minimum Clinical Recommendations for diagnosis,
treatment and follow-up of small-cell lung cancer (SCLC)
Incidence
. The crude incidence of lung cancer in the European Union
is 52.5/100 000 per year, the mortality 48.7/100 000 per
year. Among men the rates are 82.5 and 77.0/100 000 per
year, among women 23.9 and 22.3/100 000 per year,
respectively. SCLC accounts for 20% of all cases. About
90% of lung cancer mortality among men (and 80% among
women) is attributable to smoking.
Diagnosis
. Pathological diagnosis should be made according to the
World Health Organisation classification from a broncho-
scopic, Tru-cut or surgical biopsy or fine needle aspiration.
Staging and risk assessment
. Patients are usually staged according to a simple two-stage
system developed by the Veteran’s Administration Lung
Cancer Study Group as limited disease (LD) or extensive
disease (ED):
Limited disease
. The definition is based on the possibility of encompassing
all detectable tumor within a “tolerable” radiotherapy port.
Patients with limited disease have tumor deposits restricted
to one hemithorax with regional lymph node metastasis
including ipsilateral hilar, ipsilateral supraclavicular, med-
iastinal and contralateral hilar nodes.
Extensive disease
. It represents any tumor beyond the bounds defined above
including ipsilateral lung metastases and malignant pleural
effusion.
. In addition to a complete history and physical examination,
staging procedures should at least include the following:
chest X-ray, complete blood count, liver and renal function
tests, LDH, sodium, and a CT scan of chest and upper
abdomen.
. Additional tests to define limited disease in patients with
symptoms or abnormal physical examination suggesting
metastasis are: a bone scintigraphy, a CT scan or MRI of
the brain, and a bone marrow biopsy. Once any one of these
tests is positive, extensive disease has been confirmed and
there is no need to proceed with the rest of the tests [V, D].
Treatment
Treatment of limited disease
. Standard regimens, also for patients diagnosed at surgery,
are either based on etoposide-platinum or cyclophospha-
mide-doxorubicin and should be given for 4–6 cycles [I, A].
Maintenance chemotherapy does not result in any sub-
stantial improvement in survival [II, A].
. Etoposide-cisplatin is widely regarded as state-of-the-art
chemotherapy for limited disease, particularly because this
regimen can be combined with concurrent irradiation with-
out unacceptable toxicity [II, A].
. Chest radiotherapy increases local control and survival and
should be given to all patients with limited disease. Several
studies suggest to start thoracic radiotherapy early during
chemotherapy [II–III, A].
. Prophylactic cranial irradiation is indicated in patients with
a complete remission from limited disease because it
reduces the lifetime risk of cerebral metastases and
improves survival [II, B].
Treatment of extensive disease
. Chemotherapy with the same regimens as for limited dis-
ease and given for 4–6 cycles also improves survival for
patients with extensive disease and is usually the most
effective way to ameliorate clinical symptoms [II, A].
Second-line chemotherapy
. Patients relapsed from a response to first-line chemotherapy
should be considered for second-line chemotherapy [III, B].
Response evaluation
. Response evaluation is recommended at least at the end of
treatment by repetition of the initial radiographic tests [V, D].
Follow-up
. There is no evidence that follow-up of asymptomatic
patients is needed. Specific examinations as clinically
indicated.
Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
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considered justified standard clinical practice by the experts
and the ESMO faculty.
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